Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

@article{Wiseman2007WeightbasedDO,
  title={Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.},
  author={G. A. White J. A. Vaccaro H. M. Wiseman and Peter S. Conti and Katie Vo and Russell Schilder and Leo I Gordon and Christos Emmanouilides and Dan H Silverman and Thomas E Witzig and Mohamed Darif and Arturo Molina},
  journal={Clinical lymphoma & myeloma},
  year={2007},
  volume={7 8},
  pages={514-7}
}
BACKGROUND Ibritumomab tiuxetan radioimmunotherapy produces durable remissions in patients with relapsed/refractory indolent non-Hodgkin lymphoma. The dosing of Yttrium 90 (90Y)-ibritumomab tiuxetan is based on patient weight and platelet count: 0.4 mCi/kg in patients with a count >or= 150 x 10(9)/L, to a maximum dose of 32 mCi. Patients weighing > 80 kg with platelet counts of >or= 150 x 10(9)/L receive a lower dose per unit of body weight. We evaluated whether this influences the safety or… CONTINUE READING